News | New evidence: Ketogenic diet can improve body weight, insulin, and androgen levels in PCOS in the short term
A systematic review and meta-analysis published in the British Journal of Nutrition brings new evidence to dietary intervention research for women with polycystic ovary syndrome (PCOS): a professionally supervised "very low-carbohydrate ketogenic diet" (VLCKD) can not only significantly reduce body weight and abdominal fat, but also improve insulin resistance and lower androgen levels, thereby delivering quantifiable short-term benefits for cycle irregularities, metabolic stress, and fertility needs. However, the research team also emphasized that long-term safety, adherence, and differences among PCOS phenotypes still require further validation.
The metabolic and lifestyle challenges of PCOS make VLCKD a research focus
About one in ten women of reproductive age worldwide is affected by PCOS, characterized by insulin resistance, weight gain, low-grade inflammation, and hyperandrogenism. Even a small amount of weight loss can bring improvements in menstrual cycles and enhanced fertility potential, but many intensive diet plans are difficult to sustain in daily life. VLCKD, by inducing nutritional ketosis, lowering insulin, and reducing visceral fat, is regarded as a potentially more "feasible" dietary approach. However, most existing trials are short in duration and vary widely in protocols, and the scientific community remains cautious about its long-term use.
Systematic review included 12 RCTs, over 800 women with PCOS
The research team completed the search according to the PRISMA process and registered the study protocol in PROSPERO, ultimately including 12 randomized controlled trials from countries including Italy, China, Pakistan, and the United States, of which 11 were included in the meta-analysis. These trials covered intervention periods ranging from 4 to 24 weeks, with dietary protocols ranging from VLCKD at 750–800 kcal to energy-restricted VLCKD at 1300–1500 kcal, but all ensured ketosis through strict carbohydrate control.
The study evaluated three major categories of outcomes:
Reductions in body weight, fat, and waist circumference were highly significant
The meta-analysis showed that VLCKD has a clear effect on weight management:
Average body weight reduction of 9.57 kg
Waist circumference reduction of 7.75 cm
Fat mass reduction of 7.44 kg
Significant BMI reduction of 3.45 kg/m²
In real life, these changes translate into a visibly slimmer waist, reduced joint stress, and smoother sleep. Although heterogeneity was high for several indicators (I²>90%), sensitivity analyses maintained consistent directional results, and funnel plots showed no obvious publication bias.
Decreased androgens and increased SHBG point to improved ovulatory potential
VLCKD also produced clear hormonal improvements:
Free testosterone decreased by 0.31 ng/dL
Total testosterone decreased by 7.21 ng/dL
SHBG increased by 15.22 nmol/L
Both LH and the LH/FSH ratio decreased
No significant change was observed in FSH
The overall pattern shows decreased androgens and more stable axis hormones, which is conducive to restoring ovulatory rhythm.
Improved insulin and glucose control reduces long-term metabolic risk burden
Positive changes were also seen in metabolic parameters:
Fasting glucose decreased by 9.65 mg/dL
Fasting insulin decreased by 2.41 μIU/mL
HOMA-IR improved by 2.46
This means more stable energy and fewer episodes of sudden fatigue or "hypoglycemic crashes." Triglycerides decreased significantly, but total cholesterol, LDL-c, and HDL-c showed no consistent trend.
The evidence still has boundaries: short trials, high heterogeneity, and lack of long-term follow-up
The research team noted that most RCTs have the following limitations:
Short intervention periods make it difficult to assess long-term safety
Large differences in dietary formulations lead to high statistical heterogeneity
Inadequate randomization in some trials
No stratified analysis by PCOS phenotype
Limited reporting of adverse events and adherence
In addition, the ketogenic diet itself may cause short-term gastrointestinal discomfort, nutritional gaps, or fluctuations in some lipid parameters, so professional supervision and cyclical carbohydrate reintroduction are particularly important.
Effective in the short term, but long-term large-sample, real-world studies are still needed
Current evidence clearly shows that VLCKD can improve body weight, metabolism, and androgen levels in women with PCOS in the short term, and may promote fertility-related indicators. However, the study calls for future research with longer duration, stronger controls, clear differentiation of PCOS phenotypes, and integration of behavioral support to more comprehensively evaluate the sustainability and safety of VLCKD.
Notícias | Novas evidências: dietas cetogênicas podem melhorar o peso, a insulina e os níveis de andrógenos na SOP a curto prazo
News | New evidence: Ketogenic diet can improve body weight, insulin, and androgen levels in PCOS in the short term
A systematic review and meta-analysis published in the British Journal of Nutrition brings new evidence to dietary intervention research for women with polycystic ovary syndrome (PCOS): a professionally supervised "very low-carbohydrate ketogenic diet" (VLCKD) can not only significantly reduce body weight and abdominal fat, but also improve insulin resistance and lower androgen levels, thereby delivering quantifiable short-term benefits for cycle irregularities, metabolic stress, and fertility needs. However, the research team also emphasized that long-term safety, adherence, and differences among PCOS phenotypes still require further validation.
The metabolic and lifestyle challenges of PCOS make VLCKD a research focus
About one in ten women of reproductive age worldwide is affected by PCOS, characterized by insulin resistance, weight gain, low-grade inflammation, and hyperandrogenism. Even a small amount of weight loss can bring improvements in menstrual cycles and enhanced fertility potential, but many intensive diet plans are difficult to sustain in daily life. VLCKD, by inducing nutritional ketosis, lowering insulin, and reducing visceral fat, is regarded as a potentially more "feasible" dietary approach. However, most existing trials are short in duration and vary widely in protocols, and the scientific community remains cautious about its long-term use.
Systematic review included 12 RCTs, over 800 women with PCOS
The research team completed the search according to the PRISMA process and registered the study protocol in PROSPERO, ultimately including 12 randomized controlled trials from countries including Italy, China, Pakistan, and the United States, of which 11 were included in the meta-analysis. These trials covered intervention periods ranging from 4 to 24 weeks, with dietary protocols ranging from VLCKD at 750–800 kcal to energy-restricted VLCKD at 1300–1500 kcal, but all ensured ketosis through strict carbohydrate control.
The study evaluated three major categories of outcomes:
(1) Anthropometric measures: body weight, BMI, waist circumference, fat mass, waist-to-hip ratio;
(2) Hormone levels: sex hormone-binding globulin (SHBG), LH, FSH, free and total testosterone, etc.;
(3) Metabolic markers: fasting glucose, insulin, HOMA-IR, blood lipids.
Reductions in body weight, fat, and waist circumference were highly significant
The meta-analysis showed that VLCKD has a clear effect on weight management:
Average body weight reduction of 9.57 kg
Waist circumference reduction of 7.75 cm
Fat mass reduction of 7.44 kg
Significant BMI reduction of 3.45 kg/m²
In real life, these changes translate into a visibly slimmer waist, reduced joint stress, and smoother sleep. Although heterogeneity was high for several indicators (I²>90%), sensitivity analyses maintained consistent directional results, and funnel plots showed no obvious publication bias.
Decreased androgens and increased SHBG point to improved ovulatory potential
VLCKD also produced clear hormonal improvements:
Free testosterone decreased by 0.31 ng/dL
Total testosterone decreased by 7.21 ng/dL
SHBG increased by 15.22 nmol/L
Both LH and the LH/FSH ratio decreased
No significant change was observed in FSH
The overall pattern shows decreased androgens and more stable axis hormones, which is conducive to restoring ovulatory rhythm.
Improved insulin and glucose control reduces long-term metabolic risk burden
Positive changes were also seen in metabolic parameters:
Fasting glucose decreased by 9.65 mg/dL
Fasting insulin decreased by 2.41 μIU/mL
HOMA-IR improved by 2.46
This means more stable energy and fewer episodes of sudden fatigue or "hypoglycemic crashes." Triglycerides decreased significantly, but total cholesterol, LDL-c, and HDL-c showed no consistent trend.
The evidence still has boundaries: short trials, high heterogeneity, and lack of long-term follow-up
The research team noted that most RCTs have the following limitations:
Short intervention periods make it difficult to assess long-term safety
Large differences in dietary formulations lead to high statistical heterogeneity
Inadequate randomization in some trials
No stratified analysis by PCOS phenotype
Limited reporting of adverse events and adherence
In addition, the ketogenic diet itself may cause short-term gastrointestinal discomfort, nutritional gaps, or fluctuations in some lipid parameters, so professional supervision and cyclical carbohydrate reintroduction are particularly important.
Effective in the short term, but long-term large-sample, real-world studies are still needed
Current evidence clearly shows that VLCKD can improve body weight, metabolism, and androgen levels in women with PCOS in the short term, and may promote fertility-related indicators. However, the study calls for future research with longer duration, stronger controls, clear differentiation of PCOS phenotypes, and integration of behavioral support to more comprehensively evaluate the sustainability and safety of VLCKD.
Story source:
Collected from the internet